🏆 La Cámara Peruana de Comercio Exterior OFICIAL desde 2011 • ENIEX • Member of Internationally United Commercial Agents and Brokers • Google Workspace School • +40,000 alumnos certificados Conoce nuestra historia
0Contactanos
by Soporte CamexFDA
Weekend Watch VI Vol. I · Núm. 035
VIE · 26.JUN.2026 Lima — Perú 07:45 UTC-5

C
CAMEX  ·  FDA SERVICES DIVISION

FDA Briefing
Diario.

Edición № 035. Weekend Watch VI · cierre Sem.6 cosmetics arc. Una semana sectorial cohesiva: Quartet operativo MoCRA (Registration + Substantiation + AER + Labeling) cerrado en 4 ediciones consecutivas. El briefing entra al weekend con 5 noticias frescas + agenda quincena hasta 10 jul (MoCRA deadline 5 días) + 5 acciones LatAm cosmetics + transición Sem.7. Lo único de Weekend Watch VI: cierre del arc sectorial más cohesivo en la serie.

Edición
№ 035
FormatoWeekend Watch VI
CierraSem.6 · quartet MoCRA
Quincena26 JUN → 10 JUL
Próxima edición29.JUN.2026 (lun)

Cierre Sem.6 cosmetics · transición a Sem.7

Sem.6 fue el arc sectorial más cohesivo de la serie hasta hoy: 4 ediciones consecutivas sobre cosmetics MoCRA. Quartet operativo cerrado: Registration (031) + Safety Substantiation (032) + AER (033) + Labeling+Claims (034). Each edición building en la previous. La doctrine completa para LatAm cosmetics manufacturers serviendo USA market. Hoy: balance + 5 frescas + agenda quincena + 5 acciones LatAm + transición Sem.7. La pregunta de transición: ¿continúa cosmetics deep-dive con Phase 2 cGMP, o pivotamos a sector different?

CAMEX FDA SERVICES · Weekend Watch VI · Cierre Semana 6 · Quartet Operativo MoCRA WW · VI
Sem.6 ediciones
4 · LUN-JUE quartet

Arc dominante
Cosmetics MoCRA · 4 secciones

Quartet cerrado
607 · 608 · 605 · 609

D-Day MoCRA
5 días · 01 JUL 2026

Weekend Watch VI · cierre cosmetics arc

4 ediciones. 4 secciones MoCRA. 1 doctrine. 5 días hasta D-Day.

La Semana 6 cerró 35 ediciones acumuladas en la serie. La diferencia operativa de esta semana vs las previas: arc sectorial más cohesivo de la serie. Quartet operativo MoCRA cerrado en 4 ediciones consecutivas — Registration (Section 607) + Safety Substantiation (Section 608) + AER (Section 605) + Labeling+Claims (Section 609). Each edición building doctrine sobre la previous. La integration es estructural: facility registered enables product listing enables substantiation records enables AE reporting enables labeling compliance. Sin uno, los otros 3 fail operationally. Para LatAm cosmetics manufacturers, el briefing entregó framework completo para MoCRA compliance.

Hoy entramos al weekend con MoCRA renewal countdown 5 días hasta deadline (1 jul 2026). La quincena 26 jun → 10 jul tiene 4 deadlines críticos: MoCRA renewal 1 jul (5 días · the big one), BHT/ADA comments 13 jul (17 días), fragrance allergen NPRM esperada mayo 2026 (ya delayed, monitoring continuous), VQIP FY2027 closure 1 sep (67 días). Plus nuevos signals emerging: Nara Organics infant formula botulism outbreak (Europe-manufactured · ongoing), PFAS report 51 chemicals en 1,744 cosmetic formulations (FDA dic 2025), Mandatory Recall Draft Guidance MoCRA enforcement framework activo. Próxima edición: LUN 29 jun (apertura Sem.7 con direction definida). La pregunta editorial: ¿continuamos cosmetics deep-dive con Phase 2 cGMP preparation, o pivotamos a sector different (devices, pharma, mariscos)? El cliente define qué viene.

35
ediciones acumuladas
en la serie hasta hoy

5
días hasta MoCRA
renewal 01 JUL 2026

17
días hasta BHT/ADA
comments 13 JUL 2026

755
días hasta D-Day
FSMA 204 · 20 JUL 2028

Balance Sem.6 · quartet operativo MoCRA

22 jun → 25 jun · arc sectorial cohesivo

Cada día · cada sección MoCRA · cada paleta.

Síntesis cronológica

031
LUN · 22 JUN

SECTION 607

MoCRA renewal countdown

Apertura · 9 días hasta deadline · 14K+ facilities globally · LatAm ~8% · Form 5066 + FEI + Cosmetics Direct · process + enforcement cascade + GMP Phase 2. Wine-mauve + rose gold.

032
MAR · 23 JUN

SECTION 608

Safety substantiation

3+ años sin FDA guidance · 6 pillars converged (CPSR weak link LatAm) · Section 605+610 records access · tríada coordinada · 7 high-risk ingredients · litigation vector. Slate-petrol + copper-bronze.

033
MIÉ · 24 JUN

SECTION 605

Adverse event reporting

15 business days clock · 30+ meses enforceable · 7 categorías serious (η disfigurement dominant) · AEMS Public Dashboard · 6 años records · foreign RP designation 3 models. Clinical green + cognac bronze.

034
JUE · 25 JUN

SECTION 609

Labeling + claims

5 requirements (4 active, 1 pending) · fragrance allergens NPRM mayo 2026 · cosmetic vs drug claims · formaldehyde-releasers ban hair smoothing · state overlay (CA Prop 65). Wine-cherry + champagne gold.

Las 5 noticias FDA del día

Selección Camex · Curado 26.JUN.2026 · 07:30 · viernes

01Nara Organics
Outbreak vivo Infant Botulism Europe-made · nationwide

Nara Organics infant formula · botulism outbreak ongoing.

FDA + CDC + California Department of Public Health investigando multistate outbreak de infant botulism vinculado a Nara Organics Whole Milk Organic Powdered Infant Formula. El 12 de junio FDA contactó a la firm; 13 jun Nara Organics agreed to recall all brand. 3 illnesses · 3 hospitalizations · 0 deaths · CA, PA, WA. Last illness onset: 31 mayo 2026. Distribución nacional Target stores + Target.com + Nara.com entre julio 2025 y junio 2026. Crítico: Nara Organics formula fue manufacturada en Europa.

Para LatAm context, el caso tiene tres lecciones operativas: (α) foreign-manufactured infant formula receives elevated FDA scrutiny — particularly post-Cronobacter Abbott Sturgis 2022; (β) infant botulism es notoriously underreported — symptoms toman 1-30 días para emerge, frequently misdiagnosed initially; (γ) cascade exposure asymmetric — single contaminated batch can distribute nationally vía major retailers (Target) durante 11 meses antes de detection. Para LatAm exporters infant formula o powder-based food products: el case demonstrates structural risk profile elevated. FDA infant formula enforcement post-Sturgis era is materially more aggressive. Foreign manufacturers operating en USA infant formula market require Cronobacter + Clostridium botulinum testing + facility inspection prep + recall plan documented operational.

“Nara Organics outbreak · Europe-manufactured infant formula · Target distribution. 11 meses entre distribution start y detection. Single batch · 3 hospitalizations. Foreign manufacturers scrutiny elevated.” — Camex · doctrina infant formula
▲ Impacto LatAm

LatAm processors exportando infant formula, powdered milk, baby foods, dietary supplements infantiles a USA: structural risk profile elevated post-Sturgis era. FDA enforcement priorities materially shifted infant nutrition desde 2022. Foreign manufacturer status combined con infant target market = highest scrutiny tier. Defense: Cronobacter + Clostridium botulinum testing programs, facility inspection readiness, recall plan formal documented + tested, supply chain transparency end-to-end.

✓ Acción Camex recomendada

Para LatAm infant nutrition exporters: (α) testing program audit (Cronobacter + Clostridium botulinum + Salmonella + Listeria minimum), (β) facility inspection readiness assessment, (γ) recall plan formal documented + annual mock testing, (δ) Cronobacter + botulinum-specific surveillance programs, (ε) USA importer + retailer communication framework con escalation protocol. Camex articula infant nutrition compliance específico post-Sturgis era.

Fuente: FDA Outbreak Investigation Infant Botulism Powdered Infant Formula (June 2026) · CDC + CDPH + IBTPP investigation · Nara Organics recall · Target distribution

Nara Organics · outbreak timeline

JUL 2025 Distribution start Target + Target.com + Nara.com JUL 2025 – JUN 2026 11 meses · undetected Europe-manufactured · nationwide 31 MAY 2026 Last illness onset 3 illnesses · CA, PA, WA 12 JUN 2026 FDA contacta firm Recall recommendation 13 JUN 2026 · RECALL Nara Organics agrees All brand · all lots HOY · 26 JUN Investigation ongoing Additional testing pending

11 meses distribución antes detection. Single foreign-manufactured batch. 3 hospitalizations · 0 deaths. Investigation ongoing.

02PFAS report
FDA PFAS report 29 DEC 2025 51 chemicals · 1,744 formulations

PFAS report FDA: 51 chemicals · 1,744 formulations.

El 29 diciembre 2025, FDA released “Report on the Use of PFAS in Cosmetic Products and Associated Risks” — mandatory deliverable bajo MoCRA. Hallazgos materiales: 51 PFAS son used en 1,744 cosmetic formulations. Top 5 categorías afectadas: (α) eye shadows, (β) face and neck products (leave-on), (γ) eyeliners, (δ) face powders, (ε) foundations. FDA evaluó los 25 most frequently used PFAS, representing approximately ~80% del usage volume.

El report es foundational document para futura regulatory action. PFAS specifically son target priority por (α) bioaccumulation potential, (β) environmental persistence (forever chemicals), (γ) emerging health concerns (cancer, immune, developmental). State-level actions ya en place: Vermont, Maine, Maryland, Colorado, Hawaii, Washington PFAS-specific restrictions. Federal action via FDA likely 2027-2028 timeline. Para LatAm cosmetics exporters, esto crea strategic decision point: continuar con PFAS-containing formulations (current legal pero subject a state restrictions + future federal action) vs proactive reformulation (cost upfront pero defensive long-term). Reformulation alternatives exist para los 5 categorías top: silicones, dimethicone, organic UV filters, mineral pigments. Cada uno tiene different cost + performance profile.

“51 PFAS · 1,744 formulations. FDA report es foundational. State actions ya activas. Federal action 2027-2028 esperada. Reformulation roadmap proactive es defensive long-term.” — Camex · doctrina PFAS strategic
▲ Impacto LatAm

LatAm color cosmetics manufacturers (México, Brasil, Argentina) con products en categorías top-5 PFAS: strategic decision point now. Continue current formulations vs proactive reformulation. State patchwork makes selling sin reformulation complex (must track 6+ state restrictions individually). Federal action coming. Reformulation timeline 12-24 meses. Cost $50K-500K per portfolio. Vs eventual federal ban with rushed implementation premium. Cost-benefit favorable for proactive movers.

✓ Acción Camex recomendada

PFAS audit para LatAm cosmetics: (α) inventory current portfolio PFAS-containing formulations (cross-reference 51-chemical FDA list), (β) identify state restrictions applicable to distribution channels, (γ) reformulation R&D investment evaluation, (δ) gradual transition timeline 12-24 meses, (ε) supplier verification PFAS-free certifications. Camex coordinates con cosmetics chemists + reformulation expertise.

Fuente: FDA PFAS Report (29 dic 2025) · MoCRA Section 3505 mandate · Cosmetics & Toiletries analysis · state PFAS restrictions tracking

PFAS · top 5 categorías afectadas

FDA PFAS REPORT · DIC 2025 α · Eye shadows ★ HIGHEST β · Face/neck leave-on leave-on γ · Eyeliners long-wear δ · Face powders powders ε · Foundations color cosm. REPORT KEY NUMBERS PFAS chemicals: 51 Formulations affected: 1,744 Top 25 evaluated: ~80% volume ★ STATE ACTIONS ACTIVE VT · ME · MD · CO · HI · WA · CA

5 categorías color cosmetics afectadas. State patchwork ya restringe. Federal action 2027-2028 likely. Reformulation proactive es defensive long-term.

035 días MoCRA
5 days remaining 01 JUL 2026 Final push

MoCRA renewal · 5 días · zona rushed.

El countdown cosmetics MoCRA renewal está en 5 días desde hoy (deadline 1 jul 2026). Zona rushed: best practice FDA era 2 semanas buffer, manejable 1 semana, rushed con <1 semana. Quien no haya iniciado renewal en este momento está operando con risk material. Portal congestion expected en últimos días pre-deadline. Para LatAm cosmetics manufacturers con deadline approaching: start hoy o tomorrow máximo.

Pero importante: el deadline NO es industry-wide single date. Es 2 años desde TU initial registration date. Si registraste 1 jul 2024, deadline 1 jul 2026. Si registraste 15 mar 2024, deadline 15 mar 2026 (already passed). Muchos LatAm operators asumiendo single date son operating non-compliant sin saberlo. Para los que ya renewed: confirm submission confirmation received + FEI status active via Cosmetics Direct portal. Para los que aún no: esta semana es operational window final. Si tu organization can’t complete in 5 días: contact Camex urgently para emergency assistance · turnaround 48-72 horas possible para straightforward cases.

“5 días. Zona rushed. Quien no ha iniciado está en exposure structural. Best practice era 2 semanas. Manejable 1 semana. Hoy es rushed submission con higher risk de portal congestion + errors.” — Camex · doctrina rushed renewal
▲ Impacto LatAm

LatAm cosmetics manufacturers operating con uncertainty sobre renewal status: esta semana es last operational window. Verification urgent: (α) check Cosmetics Direct portal para tu facility status, (β) verify FEI active + renewal complete, (γ) if renewal complete, document confirmation, (δ) if not complete, initiate hoy/mañana, (ε) if deadline already passed (early 2024 registrants), urgent corrective action required.

✓ Acción Camex recomendada

Emergency renewal assistance disponible para LatAm cosmetics manufacturers needing urgent support. Turnaround 48-72 horas para straightforward cases con: (α) FEI active + correcto, (β) facility data updated, (γ) responsible person designated, (δ) data + submission ready. Camex provides end-to-end renewal completion + verification + confirmation documentation. Contact urgently si needed.

Fuente: FDA Cosmetics Direct portal · MoCRA Section 607(a)(2) · renewal cycle 1 deadline · best practice FDA guidance

5 days · zona operativa rushed

5 DÍAS HASTA DEADLINE 01 JULIO 2026 · MIÉ First biennial renewal deadline ★ ZONA OPERATIVA Óptima (2+ sem): PASADA Manejable (1-2 sem): PASADA Rushed (<1 sem): ★ HOY

5 días = zona rushed submission. Mayor risk portal congestion + errors. Quien no inició está exposed structural. Emergency assistance available 48-72h.

04Recall mandate
Draft Guidance 18 DEC 2025 MoCRA recall authority

Mandatory recall guidance: how FDA decides.

El 18 diciembre 2025 FDA publicó Draft Guidance “Questions and Answers Regarding Mandatory Cosmetics Recalls”. Pre-MoCRA, FDA podía solo request voluntary recalls de cosmetics. Post-MoCRA, FDA tiene mandatory recall authority cuando reasonable belief de “serious adverse health consequences or death” (SAHCOD). La draft guidance establece criteria que FDA usará: significant safety observations during inspections, analytical results, epidemiological data, vulnerability of exposed populations, adverse event reports, consumer complaints, whether responsible person ya iniciated voluntary action.

La guidance ofrece examples de SAHCOD conditions: death, life-threatening events, inpatient hospitalization, birth defects, infections, various disfigurement forms. FDA conducts assessment under “customary o usual conditions of use”. El framework operativo: (α) FDA initially gives responsible person opportunity para voluntary cease distribution + recall, (β) if voluntary action inadequate, FDA escalates a formal recall order, (γ) compliance con recall order is mandatory including communication con Agency + public. Para LatAm cosmetics manufacturers: el power changes cost-benefit calculus completely. Pre-MoCRA voluntary recall era discretionary. Post-MoCRA mandatory recall can override company preferences. Defense estructural: robust safety substantiation + responsive AE management + recall plan documented + rapid voluntary action when issues emerge.

“Mandatory recall power changes calculus. Voluntary action robust = control. Slow voluntary action = FDA escalates. Sin voluntary action = mandatory order overrides company preferences.” — Camex · doctrina mandatory recall
▲ Impacto LatAm

LatAm cosmetics exporters subject a USA jurisdiction: significant operational change post-MoCRA. Pre-MoCRA, voluntary recall era manageable decision. Post-MoCRA mandatory authority creates time pressure: rapid voluntary action (within 24-48 hours of issue identification) vs FDA-imposed mandate (loss of control). Defense: AE monitoring + signal detection + escalation protocol + recall plan tested annually + USA importer communication framework documented.

✓ Acción Camex recomendada

Recall preparedness audit para LatAm cosmetics: (α) recall plan formal documented + signed by Responsible Person, (β) communication tree pre-mapeada con USA importers + distributors + retailers, (γ) production lot-level traceability, (δ) annual mock recall exercise con measurable response time targets, (ε) USA-side legal counsel relationship documented. Camex articula recall preparedness framework específico.

Fuente: FDA Draft Guidance “Questions and Answers Regarding Mandatory Cosmetics Recalls” (18 dic 2025) · MoCRA Section 611 · Venable LLP analysis · HPM FDA Law Blog

Mandatory recall · framework decision

FDA DECISION CRITERIA α · Safety observations en inspection β · Analytical results raw/finished γ · Epidemiological injury data δ · Vulnerability of populations ε · AE reports + complaints ζ · Voluntary action status ★ SAHCOD EXAMPLES Death · life-threatening · hospitalization Birth defects · infections · disfigurement ★ VOLUNTARY ACTION = CONTROL

6 decision criteria FDA uses para mandatory recall. ζ voluntary action status crítico — quick voluntary action keeps control vs slow voluntary = FDA escalates.

05Food alerts
Multi-vector signals Hepatitis A + norovirus Tejocote + cinnamon

Multi-vector food safety: Hepatitis A · norovirus · cinnamon lead.

Parallel a cosmetics arc Sem.6, FDA food safety enforcement continúa actividad sustained. Signals recientes documentados FDA Safety Alerts page: (α) Concha Negra (Black Shell) shell meat Hepatitis A alert abril 2026 — high-risk seafood category LatAm; (β) Hammersley Inlet WA shellfish norovirus abril 2026; (γ) Tejocote Root Supplements substituted con toxic yellow oleander updated marzo 2026 — particularly relevant LatAm dietary supplement category; (δ) Ground cinnamon products elevated lead updated noviembre 2025; (ε) Imported cookware lead leaching agosto 2025.

Para LatAm context, estos signals son operationally informativos beyond cosmetics arc: (i) seafood/shellfish categoría con AE + outbreak patterns continuos — LatAm marisco exporters (Perú, Chile, Ecuador, México) operating under elevated scrutiny; (ii) dietary supplements con substitution/adulteration patterns — tejocote case demonstrates traditional Latin American botanicals can be substituted con toxic alternatives; (iii) heavy metals contamination ongoing — cinnamon (often Latin American source), cookware. Patrón cumulativo: FDA enforcement opera continuously across multiple sectors. Monitoring routine 80 min/semana (cubierto № 023) catches estos signals como reading consciente, not chance encounter. Para LatAm exporters multi-sector: monitoring requires coverage de cosmetics + food + supplements + seafood + cookware si applicable.

“Multi-vector food safety signals. Hepatitis A · norovirus · tejocote toxic substitution · lead en cinnamon. Cada uno LatAm-relevant. Monitoring routine catches todos. Sin monitoring, blind spots compound.” — Camex · doctrina multi-vector
▲ Impacto LatAm

LatAm multi-sector exporters (food + cosmetics + supplements + seafood): monitoring scope debe cubrir todos los sectors relevantes. Single-sector monitoring insufficient para multi-sector operations. Particular elevated attention required para: marisco/shellfish exporters (Hepatitis A + norovirus continuous), dietary supplement makers con traditional Latin American botanicals (substitution risk + adulteration), spice exporters (heavy metals testing critical), cookware (lead leaching). Camex Intelligence Brief cubre todos los sectors.

✓ Acción Camex recomendada

Multi-sector monitoring routine para LatAm exporters: (α) FDA Recalls/Withdrawals/Safety Alerts page · weekly check, (β) FDA Warning Letters page · weekly check, (γ) sector-specific subscriptions (CFSAN, CDER, CDRH, CTP, OCC), (δ) state-level monitoring (CA, NY, FL, TX, IL prioritized), (ε) AEMS Public Dashboard para cosmetics. Combined ~2 horas/semana coverage comprehensive. Camex Intelligence Brief automates esto con LatAm-specific curation.

Fuente: FDA Food Safety Alerts & Advisories · multi-sector signals tracking · April-June 2026 cumulative · Camex monitoring framework

Multi-vector · 5 signals recientes

SIGNALS RECIENTES · MULTI-SECTOR α · CONCHA NEGRA · HEP A Abril 2026 · LatAm shellfish β · HAMMERSLEY WA · NOROVIRUS Abril 2026 · domestic shellfish ★ γ · TEJOCOTE · TOXIC SUBST Marzo 2026 · LatAm botanical δ · CINNAMON · LEAD ELEVATED Noviembre 2025 · LatAm spice ε · COOKWARE · LEAD LEACHING Agosto 2025 · LatAm/Asia imports PATRÓN CUMULATIVO 3 de 5 signals · LatAm-direct relevance

5 signals recientes · 3 LatAm-direct relevance. γ Tejocote substitution destacado — traditional botanicals substituted con toxic alternatives. Multi-sector monitoring required.

Agenda quincena · 26 jun → 10 jul

5 deadlines críticos · 14 días operativos

Lo que viene en las próximas 2 semanas.

Hot zone calendar Camex

5
DÍAS · 01 JUL 2026

MoCRA renewal

Cosmetic facility annual registration renewal. ★ THE BIG ONE. LatAm cosméticos exporters: confirm renewal completed o initiate urgently. Sin renewal, misbranded → import alert risk.

17
DÍAS · 13 JUL 2026

BHT/ADA comments

Comment deadline para BHT (butylated hydroxytoluene) + ADA (azodicarbonamide) FDA review. LatAm food processors usando estos additives: written comments opportunity.

~30
DÍAS · POST 15 JUL

Fragrance NPRM

FDA fragrance allergen NPRM esperada mayo 2026 (ya delayed). Monitoring continuous. LatAm cosmetics: pre-preparation con fragrance supplier allergen breakdowns.

67
DÍAS · 01 SEP 2026

VQIP FY2027

Voluntary Qualified Importer Program application closure FY2027. LatAm exporters via US importer relationship: opportunity para expedited entry FY2027.

755
DÍAS · 20 JUL 2028

D-Day FSMA 204

Food Traceability Rule enforcement. LatAm productos en Food Traceability List: lot-level traceability mandatory. Implementation 18-30 meses para cadenas complejas.

5 acciones fin de semana · LatAm cosmetics

27-28 jun · weekend operations

Lo que vale hacer este weekend.

Time vs impact analysis

α

MoCRA renewal final verification

★ THE PRIORITY. Check Cosmetics Direct portal facility status. Confirm renewal submitted o initiate urgently. 5 días hasta deadline. If renewal complete, save documentation. If not, esta es la última ventana operativa.

Time30-60 min

β

PFAS portfolio audit

Cross-reference current cosmetics formulations contra FDA 51-chemical PFAS list. Top 5 categorías priority: eye shadows + face/neck leave-on + eyeliners + face powders + foundations. Identify reformulation candidates.

Time2-4 hr

γ

Bilingual claims review

Inventory marketing claims actual per SKU (labels + packaging + e-commerce). Identify Spanish-English translations que preserve drug-trigger language (“trata”, “cura”, “previene” → “treats”, “cures”, “prevents”). Reformulate con “appearance” qualifier.

Time3-6 hr

δ

Infant nutrition check

Si tu organization exports infant formula/baby food/baby supplements a USA: post-Nara Organics outbreak, audit Cronobacter + Clostridium botulinum testing program. Foreign manufacturer scrutiny elevated. Recall plan ready?

Time2-3 hr

ε

AEMS monitoring setup

FDA Adverse Event Monitoring System Public Dashboard. Setup monthly query para tu brand + competitor brands. Cross-reference contra internal AE database. Identify gaps. Sin AEMS monitoring, blind spot estructural.

Time1-2 hr

Transición a Sem.7 · 3 paths

Inicio LUN 29 JUN 2026

Lo que viene · 3 paths para la Sem.7.

Editorial Camex

A
COSMETICS CONTINUE

Phase 2 cGMP

Continuar cosmetics deep-dive con Phase 2 cGMP preparation. Window 2026-2028 para early-mover competitive advantage. ISO 22716 framework. Pre-rule preparation. Cierre arc cosmetics completo.

B
SECTORIAL PIVOT

Sector nuevo

Pivot a sector different post-renewal MoCRA: pharma LatAm? Devices LatAm post-QMSR? Mariscos LatAm extendido? Dietary supplements LatAm? Cada sector merece su semana profundizada.

C
POST-DEADLINE

Post-MoCRA analysis

Sem.7 dedicada a post-MoCRA deadline analysis: industry stress test results, FDA enforcement patterns observed, LatAm-specific lessons learned, comparative outcomes vs predictions. Reactive analytical.

★ EDITORIAL DECISION POINT

Sem.6 cosmetics arc fue el más cohesivo de la serie. La pregunta natural: ¿continuar profundizando cosmetics (Path A · cGMP Phase 2) hasta cierre completo del sector? ¿O pivotar a sector nuevo (Path B · pharma/devices/mariscos)? ¿O esperar 5 días hasta deadline pasara y analizar lo aprendido (Path C · post-deadline)? Cada path tiene mérito específico. Path A entrega cosmetics framework completo. Path B diversifica el briefing portfolio. Path C aprovecha el momento histórico del primer renewal. Camex evaluará feedback de clientes + emerging events durante weekend. Lunes 29 jun: edición № 036 con direction definida.

35 ediciones. 6 semanas. 6 Weekend Watches. Quartet MoCRA cerrado.

El briefing alcanza 35 ediciones acumuladas en 6 semanas. Sem.6 fue el arc sectorial más cohesivo de la serie: Quartet operativo MoCRA cerrado en 4 ediciones consecutivas (Sections 607 + 608 + 605 + 609). Doctrine completa para LatAm cosmetics manufacturers serviendo USA market. Hoy Weekend Watch VI cierra Sem.6 con balance sistemático + agenda quincena + 5 acciones LatAm + 3 paths para Sem.7. El cliente define qué viene. Para LatAm cosmetics manufacturers específicamente: el momento operativo final es esta semana — 5 días hasta MoCRA renewal deadline. Quien no completa renewal está operando con risk material. Camex articula end-to-end. La pregunta no es cuándo, es cómo · ahora.

35
Ediciones acumuladas en la serie

6 Weekend
Watches publicados consecutivamente

+ 200
Empresas articuladas con Camex

Camex · FDA Briefing · Weekend Watch VI · cierre Sem.6 Edición № 035 · 26.JUN.2026 · Próxima: 29.JUN.2026 (lun) Vol I · № 035

Leave A Comment

Your email address will not be published. Required fields are marked *

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.